Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-11-25
2010-10-19
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C436S063000, C436S064000
Reexamination Certificate
active
07816084
ABSTRACT:
Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
REFERENCES:
patent: 5637471 (1997-06-01), Artavanis-Tsakonas et al.
patent: 2004/0029114 (2004-02-01), Mack et al.
patent: 2004/0038207 (2004-02-01), Orntoft
patent: 2004/0072154 (2004-04-01), Morris et al.
patent: 2004/0156854 (2004-08-01), Mulligan et al.
patent: 2004/0253606 (2004-12-01), Aziz et al.
patent: 2005/0181375 (2005-08-01), Aziz et al.
patent: 2006/0121511 (2006-06-01), Lee et al.
patent: 2006/0234287 (2006-10-01), Erlander et al.
patent: 2006/0286586 (2006-12-01), Drexhage et al.
patent: 2007/0037145 (2007-02-01), Morris et al.
patent: 2007/0059706 (2007-03-01), Yu et al.
patent: 2007/0065888 (2007-03-01), Ring et al.
patent: 2007/0172844 (2007-07-01), Lancaster et al.
patent: 2007/0178090 (2007-08-01), Sukumar et al.
patent: 2007/0237770 (2007-10-01), Lai et al.
patent: 2008/0318228 (2008-12-01), Lee et al.
patent: 2009/0004173 (2009-01-01), Evans et al.
patent: 2009/0092973 (2009-04-01), Erlander et al.
patent: 2009/0105167 (2009-04-01), Potti et al.
patent: 1538218 (2005-06-01), None
patent: WO-9407522 (1994-04-01), None
patent: WO-9408037 (1994-04-01), None
patent: WO-2004053066 (2004-06-01), None
patent: WO-2005054513 (2005-06-01), None
patent: WO-2006089233 (2006-08-01), None
patent: WO-2006125195 (2006-11-01), None
International Search Report for PCT/US2008/084685, Nov. 25, 2008.
Kulkarni, S. et al., 2008, “TLE3 as a biomarker for taxane sensitivity in breast cancer,”J. Clinical Oncology, 26(15S):573.
Kulkarni, SA et al., 2009, “TLE3 as a candidate biomarker of response to taxane therapy,”Breast Cancer Research, 11(2):R17.
Leo, Di et al., 2002, “Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002,”Int. J. Clin. Oncol., 7:245-53.
Nakaya, HI et al., 2007, “Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors,”Biochemical and Biophysical Research Communications, 364(4):918-923.
National Institutes of Health Consensus Development Panel, 2001, “NIH Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, Nov. 1-3, 2000,”J. Nat. Cancer Inst. Monographs, 30:5-15.
Paik et al., 2000, “HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15,”J. Nat'l Cancert Institute, 92(24):1991-1998.
Ross, DT et al., 2007, “A differentiation based immunohistochemical classifier that is prognostic for head and neck tumor patients,”Modern Pathology, 20(2S):228A.
Ton, Van Agthoven et al., 2009, “Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance,”J. Clin. Oncology, 27(4):542-549.
United Kingdom Search Report, GB0910374.8, Aug. 7, 2007.
Beck Rodney A.
Ring Brian Z.
Ross Douglas T.
Seitz Robert S.
Applied Genomics, Inc.
Bausch Sarae
Choate Hall & Stewart LLP
Clouse Katherine Nicole
Lyon Charles E.
LandOfFree
TLE3 as a marker for chemotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TLE3 as a marker for chemotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TLE3 as a marker for chemotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228857